CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Diasome Pharmaceuticals, Inc., a clinical stage diabetes therapeutics company, announced today that it has raised a Series B round of financing, co-led by Philadelphia based Quaker BioVentures and Devon Park Bioventures. The BioAdvance Venture Fund also participated as in investor in the round. Terms of the financing are not being disclosed. Diasome plans to use the financing to fund the late-stage human clinical testing of the Company’s Oral HDV-Insulin and to continue the development of the various HDV Insulin dose forms.
